SAN DIEGO, CA / ACCESSWIRE / March 22, 2016 / Imprimis Pharmaceuticals, Inc. (IMMY) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to ...

(Reuters) - Shares of Imprimis Pharmaceuticals Inc <IMMY.O> sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's <AGN.N> ...

(Reuters) - Compounding pharmacy Imprimis Pharmaceuticals Inc said on Wednesday it plans to make a cheaper alternative to Retrophin Inc's kidney stone drug, Thiola. Retrophin, under former Chief ...

Imprimis Pharmaceuticals in San Diego said it has introduced a drug to treat lead poisoning that’s far less expensive than the brand-name medication currently offered by Valeant Pharmaceuticals. The ...

Good afternoon and welcome to the conference call covering Imprimis Pharmaceuticals Financial Results and Business Update for the First Quarter 2018. My name is Sherry and I will be your operator for ...

Imprimis Pharma ($IMMY) is striking out at notorious price hikes once again. The compounder that rolled out a cheaper alternative to toxoplasmosis treatment Daraprim ...

SAN DIEGO, Feb. 10, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded ...

SAN DIEGO, May 4, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced the launch of its new patent-pending Simple ...

SAN DIEGO, July 23, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development ...

SAN DIEGO, June 29, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has entered into an agreement to sell its ...

, which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced that as part of the recently announced Buderer Drug Company Asset ...